Published in Psychopharmacology (Berl) on June 12, 2010
Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety. Nat Neurosci (2011) 1.46
Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl) (2015) 0.81
Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice. Eur J Pharmacol (2012) 0.79
Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice. Psychopharmacology (Berl) (2014) 0.77
Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice. Psychopharmacology (Berl) (2015) 0.76
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) (2001) 5.67
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) (2001) 4.52
Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) (2008) 2.64
Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) (1997) 2.26
Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res (1998) 2.21
Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem (1997) 2.08
Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry (2002) 2.04
Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry (1994) 1.90
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther (2008) 1.60
Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry (2001) 1.55
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther (2009) 1.35
Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J Pharmacol Exp Ther (2004) 1.27
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience (2006) 1.22
Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology (2006) 1.15
Psychopharmacology of dopamine: the contribution of comparative studies in inbred strains of mice. Prog Neurobiol (1997) 1.09
Dopamine in the medial prefrontal cortex controls genotype-dependent effects of amphetamine on mesoaccumbens dopamine release and locomotion. Neuropsychopharmacology (2004) 1.07
The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav (1997) 1.06
Antipsychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology (2006) 1.04
The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology (Berl) (2001) 1.02
Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol Psychiatry (2006) 1.00
"Paradoxical" effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology. Neuropharmacology (1979) 0.99
The effects of dopamine agonists on prepulse inhibition in healthy men depend on baseline PPI values. Psychopharmacology (Berl) (2005) 0.98
Amphetamine effects on startle gating in normal women and female rats. Psychopharmacology (Berl) (2009) 0.98
Exposure to an augmented acoustic environment alters auditory function in hearing-impaired DBA/2J mice. Hear Res (1998) 0.97
Comparisons of behavioral and neurochemical characteristics between WKY, WKHA, and Wistar rat strains. Neuropsychopharmacology (2002) 0.94
Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle. J Pharmacol Exp Ther (2008) 0.92
Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. Pharmacol Biochem Behav (2007) 0.92
Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl) (2002) 0.92
Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons. Psychopharmacology (Berl) (2002) 0.91
Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains. Eur J Pharmacol (2001) 0.88
Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry (1999) 0.88
Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice. Psychopharmacology (Berl) (2009) 0.87
Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice. Psychopharmacology (Berl) (2009) 0.85
Experience increases the prepulse inhibition of the acoustic startle response in mice. Behav Neurosci (2006) 0.84
Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice. Psychopharmacology (Berl) (2006) 0.82
Effects of caffeine on sensorimotor gating of the startle reflex in normal control subjects: impact of caffeine intake and withdrawal. Psychopharmacology (Berl) (2000) 0.82
Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (Berl) (1997) 0.82
Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl) (2008) 0.81
Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur J Pharmacol (1999) 0.79
Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine. J Pharmacol Exp Ther (1999) 0.78
Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice. Psychopharmacology (Berl) (2007) 0.78
A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol (1995) 0.78
Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci (2005) 1.57
Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci (2003) 1.55
The neuropharmacology of the ketogenic diet. Pediatr Neurol (2007) 1.54
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. J Med Chem (2008) 1.28
Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J Pharmacol Exp Ther (2005) 1.24
Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations. J Cell Physiol (2002) 1.22
Effects of cocaine under concurrent fixed ratio schedules of food and IV drug availability: a novel choice procedure in monkeys. Psychopharmacology (Berl) (2002) 1.03
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem (2008) 1.03
Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. J Med Chem (2007) 1.00
Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia (2007) 0.96
Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J Pharmacol Exp Ther (2008) 0.96
Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol (2009) 0.95
NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology (2002) 0.93
The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep (2009) 0.92
Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol Biochem Behav (2006) 0.92
Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. Eur J Pharmacol (2003) 0.90
Acute seizure tests in epilepsy research: electroshock- and chemical-induced convulsions in the mouse. Curr Protoc Pharmacol (2009) 0.90
Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J Pharmacol Exp Ther (2002) 0.89
Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther (2005) 0.86
Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice. Psychopharmacology (Berl) (2009) 0.85
Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment. Biochem Pharmacol (2007) 0.85
Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology (2011) 0.84
CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther (2011) 0.81
Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem Pharmacol (2010) 0.81
Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan. Pharmacol Biochem Behav (2003) 0.80
Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor. J Med Chem (2007) 0.80
Ketogenic diet increases concentrations of kynurenic acid in discrete brain structures of young and adult rats. J Neural Transm (Vienna) (2011) 0.79
Detection of low level histamine H3 receptor occupancy by autoradiography. J Neurosci Methods (2009) 0.79
Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice. Psychopharmacology (Berl) (2007) 0.78
Effects of cocaine-kindling on the expression of NMDA receptors and glutamate levels in mouse brain. Neurochem Res (2010) 0.77
The phosphatidylinositol 3-kinase inhibitor LY 294002 inhibits GlyT1-mediated glycine uptake. Brain Res (2008) 0.77
The anticonvulsant activity of acetone does not depend upon its metabolites. Epilepsia (2008) 0.76
Modulation of excitatory transmission onto midbrain dopaminergic neurons of the rat by activation of group III metabotropic glutamate receptors. Ann N Y Acad Sci (2003) 0.76
Pharmacodynamic and pharmacokinetic interactions between common antiepileptic drugs and acetone, the chief anticonvulsant ketone body elevated in the ketogenic diet in mice. Epilepsia (2008) 0.76
Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse. Psychopharmacology (Berl) (2011) 0.76
Anesthetic Implications of Ebola Patient Management: A Review of the Literature and Policies. Anesth Analg (2015) 0.75
Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis. J Neurosci (2014) 0.75
A Threat-based, Statewide EMS Protocol To Address Lifesaving Interventions In Potentially Volatile Environments. J Spec Oper Med (2016) 0.75
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem (2011) 0.75
[Anticonvulsant and neuroprotective effects of the ketogenic diet]. Przegl Lek (2010) 0.75
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties. J Med Chem (2013) 0.75
Ketogenic diet attenuates NMDA-induced damage to rat's retinal ganglion cells in an age-dependent manner. Ophthalmic Res (2015) 0.75
Influence of some convulsant agents on the protective activity of a novel antiepileptic drug, felbamate, against maximal electroshock in mice. Pol J Pharmacol (2003) 0.75
Characterization of pharmacological and wake-promoting properties of the dopaminergic stimulant sydnocarb in rats. J Pharmacol Exp Ther (2011) 0.75